TrialThe Lancet. Global health2022

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.

Deborah Watson-Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.